我国生物制药产业的现状及发展建议  

Status Quo and Development Proposals of Biopharmaceutical Industry in China

作　　者：陶然[1] 余正[1] 

机构地区：[1]中国药科大学国际医药商学院,南京211198

出　　处：《中国药房》2012年第37期3463-3465,共3页China Pharmacy

摘　　要：目的:为我国生物制药产业的发展提供参考和建议。方法:总结目前我国生物制药产业的现状、政府出台的多项支持政策和"新医改"对其的影响,并对我国生物制药产业的发展提出建议。结果:我国生物制药产业发展迅速,但资金投入量和行业集中度均较低;政府出台了多项支持政策,如2011年的《医药工业"十二·五"规划》和税收优惠等;"新医改"增加了诊断试剂用量,促进了资本进入。结论:我国生物制药产业应加快产业升级,引入企业与高校合作的研发模式,重视自身专利申请和保护,借助研发"外包"的机会不断在产业结构、专利技术、研发水平3个层面上有所突破。OBJECTIVE： To provide reference and suggestion for the development of biopharmaceutical industry in China. METHODS ： The status quo of biopharmaceutical industry in China and the effects of support policy and New Medical Reform is- sued by government on biopharmaceutical industry were summarized, and suggestions on the development of the industry were put forward. RESULTS： Biopharmaceutical industry developed rapidly in China, and input amount and industry concentration of the fund were in low level; various support policies were issued by government, such as Pharmaceutical Industry ＂Twelfth Five-Year Plan＂ in 2011 and tax preference; New Medical Reform increased the amount of diagnostic reagent and promoted fund input. CON- CLUSIONS： It is suggested to upgrade biopharmaceutical industry, introduce the R＆D mode of cooperation of enterprises and uni- versities, focus on the application and protection of self-patent and strive for breakthrough in industry structure, patent and technolo- gy and R＆D with taking the opportunity of R＆D outsourcing.

关 键 词：生物制药 产业 现状 机遇 建议 

分 类 号：R95[医药卫生—药学]